1
|
Shimao D, Sunaguchi N, Otsuka N, Ichihara S, Nishimura R, Iwakoshi A, Yuasa T, Ando M. Three-dimensional and mesoscopic scale fine structures of human upper abdominal organs revealed by micro refraction-contrast x-ray CT. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00555-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
2
|
Miyabe-Nishiwaki T, Kaneko A, Yamanaka A, Maeda N, Suzuki J, Tomonaga M, Matsuzawa T, Muta K, Nishimura R, Yajima I, Eleveld DJ, Absalom AR, Masui K. Propofol infusions using a human target controlled infusion (TCI) pump in chimpanzees (Pan troglodytes). Sci Rep 2021; 11:1214. [PMID: 33441704 PMCID: PMC7806914 DOI: 10.1038/s41598-020-79914-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 12/15/2020] [Indexed: 11/09/2022] Open
Abstract
Chimpanzees are genetically and physiologically similar to humans. Several pharmacokinetic models of propofol are available and target controlled infusion (TCI) of propofol is established in humans, but not in chimpanzees. The purpose of this study was to investigate if human pharmacokinetic models can accurately predict propofol plasma concentration (Cp) in chimpanzees and if it is feasible to perform TCI in chimpanzees. Ten chimpanzees were anaesthetized for regular veterinary examinations. Propofol was used as an induction or maintenance agent. Blood samples were collected from a catheter in a cephalic vein at 3–7 time points between 1 and 100 min following the propofol bolus and/or infusion in five chimpanzees, or TCI in six chimpanzees. Cp was measured using high-performance liquid chromatography. The Marsh, Schnider and Eleveld human pharmacokinetic models were used to predict Cp for each case and we examined the predictive performances of these models using the Varvel criteria Median PE and Median APE. Median PE and Median APE for Marsh, Schnider and Eleveld models were within or close to the acceptable range. A human TCI pump was successfully maintained propofol Cp during general anesthesia in six chimpanzees. Human propofol pharmacokinetic models and TCI pumps can be applied in chimpanzees.
Collapse
Affiliation(s)
| | - A Kaneko
- Primate Research Institute, Kyoto University, Inuyama, Aichi, Japan
| | - A Yamanaka
- Primate Research Institute, Kyoto University, Inuyama, Aichi, Japan
| | - N Maeda
- Primate Research Institute, Kyoto University, Inuyama, Aichi, Japan
| | - J Suzuki
- Primate Research Institute, Kyoto University, Inuyama, Aichi, Japan
| | - M Tomonaga
- Primate Research Institute, Kyoto University, Inuyama, Aichi, Japan
| | | | - K Muta
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - R Nishimura
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - I Yajima
- Department of Pharmacy, National Defense Medical College Hospital, Tokorozawa, Saitama, Japan
| | - D J Eleveld
- University Medical Center Groningen, Groningen, Netherlands
| | - A R Absalom
- University Medical Center Groningen, Groningen, Netherlands
| | - K Masui
- Department of Anesthesiology, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan.
| |
Collapse
|
3
|
Shinada M, Saeki K, Yoshitake R, Eto S, Tsuboi M, Chambers JK, Uchida K, Kato D, Yoshimoto S, Kamoto S, Ikeda N, Kinoshita R, Fujita N, Nishimura R, Nakagawa T. Evaluation of epithelial and mesenchymal cell markers in canine urinary bladder transitional cell carcinoma. Vet J 2020; 266:105571. [PMID: 33323173 DOI: 10.1016/j.tvjl.2020.105571] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 10/21/2020] [Accepted: 11/03/2020] [Indexed: 02/07/2023]
Abstract
Canine transitional cell carcinoma (cTCC) is the most common malignant tumour in the urinary bladder: it is highly invasive and exhibits metastatic characteristics. Inflammation is also strongly related to cTCC. Epithelial tumours often exhibit a mesenchymal cell phenotype during tumour invasion and metastasis owing to epithelial-mesenchymal transition (EMT), which is often induced in chronic inflammation. The aim of this retrospective study was to investigate the expression of epithelial and mesenchymal cell markers in tumour cells and to evaluate its relationship with prognosis of cTCC. In this study, 29 dogs with cTCC who underwent surgical treatment were enrolled. Clinical parameters were reviewed using medical records. Tissue expression of epithelial and mesenchymal markers was evaluated by immunohistochemical analysis. The association between the expression of mesenchymal cell markers and clinical parameters, including prognosis, was statistically examined. In five normal bladder tissues used as controls, no expression of mesenchymal markers was observed, except for one tissue that expressed fibronectin. Conversely, epithelial tumour cells expressed vimentin and fibronectin in 23/29 and 19/28 cTCC tissues, respectively. Regarding clinical parameters, vimentin score in Miniature Dachshunds was significantly higher than those in other dog breeds (P < 0.001). Multivariate survival analyses revealed that age>12 years was related to shorter progression-free survival (P = 0.02). Higher vimentin score, lower fibronectin score, and advanced clinical T stage were significantly correlated with shorter median survival time (P < 0.05). The results of this study indicate that vimentin expression was associated with cTCC progression. Further studies are needed to examine the incidence and relevance of EMT in cTCC.
Collapse
Affiliation(s)
- M Shinada
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - K Saeki
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| | - R Yoshitake
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - S Eto
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - M Tsuboi
- Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-Ku, Tokyo 113-8657, Japan
| | - J K Chambers
- Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-Ku, Tokyo 113-8657, Japan
| | - K Uchida
- Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-Ku, Tokyo 113-8657, Japan
| | - D Kato
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - S Yoshimoto
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - S Kamoto
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - N Ikeda
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - R Kinoshita
- Veterinary Medical Center, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-Ku, Tokyo 113-8657, Japan
| | - N Fujita
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - R Nishimura
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - T Nakagawa
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| |
Collapse
|
4
|
Tsuka T, Nishimura R, Hishinuma M, Murahata Y, Yamashita M, Azuma K, Osaki T, Ito N, Okamoto Y, Imagawa T. Reliability of ultrasonographic measurements of bovine sole structures in relation to sole horn thickness, measured by computed tomography, and sole horn hardness. J Dairy Sci 2019; 102:10105-10118. [PMID: 31521343 DOI: 10.3168/jds.2018-15175] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Accepted: 06/03/2019] [Indexed: 11/19/2022]
Abstract
The goal of the present study was to determine the effect of sole horn thickness (SHT) and sole horn hardness (SHD) on ultrasonographic visualization of sole structures in the inner and outer claws of 150 Holstein-Friesian cows, and to evaluate different ultrasound frequencies for this purpose. Ultrasonographic views of the sole structure were considered complete when 3 echogenic lines, representing the ventral surface of the sole horn, the borders of the sole horn and soft-tissue layer, and the ventral surface of the distal phalanx, were seen. The proportion of complete ultrasonographic views of the sole structures, designated as the ultrasonographic visualization proportion (UVP), and the measurement errors of SHT were evaluated by comparing images from computed tomography (CT) and ultrasonography. The latter images were generated using 3 different probes, frequencies of 6.5 and 5.0 MHz, and 2 different ultrasound machines (#1 and #2) to assess the apex, middle, and heel regions of the claws. The UVP were 60.8 to 77.9% for the 6.5-MHz probe in ultrasound machine #1 (probe A), which were lower than those (>90%) for both the 5.0-MHz probe in ultrasound machine #1 (probe B) and the 5.0-MHz probe in ultrasound machine #2 (probe C). The UVP was significantly lower in claws with an SHD ≥50 units than in claws with an SHD <40 or 40 to <50 units (UVP: 77.1% compared with 93.7 and 91.4%, respectively) when measured with probe B. In claws with an SHT <10 mm, the UVP was significantly lower when SHD was ≥50 units compared with <40 or 40 to >50 units; the values were 69.0% versus 91.3 and 85.9%, respectively, for probe A, and 89.7% versus 100 and 100%, respectively, for probe B. When SHT were measured by either probes A or B in ultrasound machine #1, the proportions of claws in which ultrasonographic values were within a ±1 mm range compared with the values obtained by CT were 84.9 to 91.3% for CT-determined SHT <5 mm, 66.7 to 71.9% for CT-determined SHT 5 to <7 mm, 28.9 to 51.2% for CT-determined SHT 7 to <10 mm, and 6.2 to 19.7% for CT-determined SHT ≥10 mm. The data indicated that increased SHT was associated with a decrease in ultrasonographic measurement accuracy. In claws with an SHT <5 mm, the high proportion of ultrasonographic values that were accurate within a ±1 mm range suggests that this imaging modality would be useful in cows with thin soles.
Collapse
Affiliation(s)
- T Tsuka
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550.
| | - R Nishimura
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550
| | - M Hishinuma
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550
| | - Y Murahata
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550
| | - M Yamashita
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550
| | - K Azuma
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550
| | - T Osaki
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550
| | - N Ito
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550
| | - Y Okamoto
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550
| | - T Imagawa
- Department of Veterinary Clinical Medicine, School of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4-101 Koyama-Minami, Tottori, Japan, 680-8550
| |
Collapse
|
5
|
Tomita A, Mochizuki H, Tsuboi M, Ogura I, Igarashi H, Goto-Koshino Y, Takahashi M, Ohmi A, Tomiyasu H, Ohno K, Nakagawa T, Uchida K, Nishimura R, Tsujimoto H. Development of canine X-chromosome inactivation pattern analysis for the detection of cell clonality by incorporating the examination of the SLIT and NTRK-like family member 4 (SLITRK4) gene. Res Vet Sci 2019; 125:170-175. [PMID: 31247472 DOI: 10.1016/j.rvsc.2019.06.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2018] [Revised: 06/09/2019] [Accepted: 06/10/2019] [Indexed: 01/10/2023]
Abstract
X-chromosome inactivation pattern (XCIP) analysis can be used to assess the clonality of cell populations of various origin by distinguishing the methylated X chromosome from the unmethylated X chromosome. In this study, the utility of XCIP analysis was improved by incorporating the examination of AC dinucleotide repeats in SLIT and NTRK-like family member 4 (SLITRK4) gene into the previously reported CAG repeat examination of androgen receptor (AR) gene in dogs. The rate of heterozygosity when both genes were analysed (125/150, 83.3%) was higher than AR gene examination alone (86/150, 57.3%). Blood samples from heterozygous dogs in either AC-1 or AC-2 of SLITRK4 gene were examined for the corrected inactivation allele ratio (CIAR), resulting in the determination of a reference range of CIAR <3.8 in non-neoplastic cell/tissue samples. Using this analytical method, 49% (21/43) of neoplastic tissue samples from dogs showed a CIAR >3.8, indicating the presence of a clonal population. Through the present study, the availability of canine XCIP analysis was improved by incorporating the examination of the SLITRK4 gene, providing a highly useful laboratory examination system for the detection of the clonality of various cell/tissue samples in dogs.
Collapse
Affiliation(s)
- A Tomita
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - H Mochizuki
- Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Drive, Raleigh, NC 27607, USA
| | - M Tsuboi
- Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, the University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - I Ogura
- KOJIMA Animal Hospital, KOJIMA Co., Ltd., 3-60-21 Kameido, Koto-ku, Tokyo 136-8510, Japan
| | - H Igarashi
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - Y Goto-Koshino
- Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, the University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - M Takahashi
- Laboratory of Small Animal Internal Medicine, Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima-shi, Kagoshima 890-0065, Japan
| | - A Ohmi
- Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, the University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - H Tomiyasu
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - K Ohno
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - T Nakagawa
- Department of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - K Uchida
- Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - R Nishimura
- Department of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - H Tsujimoto
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| |
Collapse
|
6
|
Park Y, Akabane H, Watanabe T, Takahashi M, Sagara Y, Nishimura R, Tsurutani J, Takashima T, Fujisawa T, Hozumi Y, Uemura Y, Mukai H. Abstract P1-14-07: Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)–A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)–. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-14-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Anthracycline-containing regimens and taxane have been standard as the first-line chemotherapy for metastatic breast cancer (MBC). We conducted SELECT BC (randomized phase 3 study of taxane versus S-1 as first-line treatment for MBC) for evaluating the efficacy of S-1 for patients with HER2-negative MBC from 2006 to 2010 in Japan. This study demonstrated non-inferiority of S-1 in overall survival (OS) (median OS was 37.2 months in taxes group and 35.0 months in S-1 group (HR 1.05, 95% CI 0.86–1.27, p=0.015)), and superiority in health-related quality of life (HRQOL) to taxanes. S-1 was also shown as less toxic than taxane (Lancet Oncol 2016; 17: 90-98). S-1 might provide clinical benefit as first-line treatment for patients with HER2-negative MBC. To confirm this suggestion, we have conducted further study (randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for HER2-negative MBC: SELECT BC-CONFIRM) from 2011 to present, and a combined analysis of two randomized studies (SELECT-BC CONFIRM and SELECT-BC).
Methods: In SELECT BC-CONFIRM, 230 patients receiving first-line treatment for MBC were randomly assigned to either anthracycline group (n=115) or S-1 group (n=115). Anthracycline group patients received anthracycline-containing regimens (AC, EC, FAC, FEC, q3w) at the discretion of the treating physician. S-1 group patients received S-1 40–60 mg twice daily based on the patient's body surface area for 28 days on, 14-day off. The primary endpoint was OS, and secondary endpoints were progression-free survival (PFS), time to treatment failure (TTF), adverse events, HRQOL, and cost-effectiveness. The results were combined with SELECT-BC, to confirm the hypothesis that S-1 treatment is not inferior to the standard therapy (taxanes / anthracycline) for HER2-negative MBC.
Results: A combined analysis of the two studies showed that HR was 1.06, 95%CI 0.90-1.253, and p=0.0071 between the standard therapy group and S-1 group. In addition, the Bayesian posterior probability for which HR would be less than 1.333 was about 99.6%.
Conclusions: A combined analysis of SELECT BC-CONFIRM and SELECT BC clearly demonstrated that OS with S-1 was not inferior to that with the standard therapy in patients receiving first-line treatment for HER2-negative MBC. S-1 could become a standard therapy for this patient population.
Citation Format: Park Y, Akabane H, Watanabe T, Takahashi M, Sagara Y, Nishimura R, Tsurutani J, Takashima T, Fujisawa T, Hozumi Y, Uemura Y, Mukai H. Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)–A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)– [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-14-07.
Collapse
Affiliation(s)
- Y Park
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - H Akabane
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - T Watanabe
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - M Takahashi
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - Y Sagara
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - R Nishimura
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - J Tsurutani
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - T Takashima
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - T Fujisawa
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - Y Hozumi
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - Y Uemura
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - H Mukai
- Tohoku Medical and Pharmaceutical University, Faculty of Medicine, Sendai, Japan; Hokkaido P. W. F. A. C. Asahikawa-Kosei General Hospital, Asahikawa, Japan; National Hospital Organization, Sendai Medical Center, Sendai, Japan; National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Hakuaikai Medical Corp Sagara Hospital, Kagoshima, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; Kindai University, Faculty of Medicine, Osakasayama, Japan; Osaka City University, Graduate School of Medicine, Osaka, Japan; Gunma Prefectural Cancer Center, Ota, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Japan; The University of Tokyo Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| |
Collapse
|
7
|
Araki K, Fujisawa T, Sakamaki K, Kikawa Y, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N. Abstract P4-13-09: Sequential second line endocrine therapy is still an effective strategy for postmenopausal ER+ and HER2- advanced breast cancer with low sensitivity to initial endocrine therapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-13-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:It is unclear how to define responsiveness to endocrine therapy (ET) during the clinical course of advanced breast cancer (ABC), especially in evaluation of the effect of sequential ET. Objective:The goal of the study was to evaluate the efficacy of second line treatment of physician's choice (2nd-line TPC) for estrogen receptor-positive (ER+) and HER2-negative postmenopausal ABC with very low or low sensitivity to initial ET. Methods:A multicenter prospective observational cohort study was performed for 2nd-line TPCs. ABC with low sensitivity to initial ET was defined as recurrence within 5 years (yrs) during adjuvant ET or progression within 9 months (mo.) of initial ET. Similarly, ABC with very low sensitivity to initial ET was defined as recurrence within 2 yrs during adjuvant ET or progression within 3 mo. of initial ET. The expected clinical benefit rate (CBR: defined as patients who achieved CR, PR or SD for 24 weeks) was 50%. The null hypothesis of a CBR of 30% was tested with a one-sided α of 5%. 90% confidence intervals (CIs) were calculated for hypothesis tests. Results: A total of 56 patients (pts) were enrolled, but 7 were ineligible and one discontinued before starting the protocol treatment. The median age was 66 yrs (range: 41-88) and the median BMI was 23.4 kg/m2 (16.4-31.9). All pts were ER+ and 80% were PgR+. Most of pts had a baseline PS of 0 or 1, 90% had invasive ductal carcinoma, and 10% had invasive lobular carcinoma. Postoperative recurrence was detected in 84% and these pts had a median duration of adjuvant ET of 30.5 mo. (5.3-58.9). De novo stage IV ABC was present in 16%, with a median duration of first-line ET of 5 mo. (2.3-10.8). Adjuvant chemotherapy including anthracycline- and/or a taxane-containing regimen was administered in 58% (29/49). As adjuvant ET before initial recurrence, 34 pts received non-steroidal aromatase inhibitors (AIs) (88.0%), 1 received a steroidal AI (2.3%), and 3 received a selective estrogen receptor modulator (SERM). As first line ET in de novo stage IV, 7 pts (14%) were treated with AIs or a SERM (1 case). 2nd-line TPCs were also used, with 40 pts receiving fulvestrant (82%), 5 receiving SERMs (10%), 3 receiving a mTOR inhibitor plus a steroidal AI (6%), and one patient receiving an AI alone. The overall CBR was 44.9% (90% CI: 34.6-57.6, p=0.009), and CBR was similar across following subgroups (PgR+: n=39, 51.3%, 90% CI: 39.6-65.2, p=0.0016; very low sensitivity group: n=17, 58.8%, 90% CI: 42.0-78.8, p=0.003; non-visceral metastases: n=25, 40%, 90% CI; 34.1-65.9, p=0.0175). However, there were not statistically significant CBR in PgR- (n=10, 20.0%, 90% CI; 8.73-50.7, p=0.617), fulvestrant subgroup (n=40, 40.0 %, 90% CI; 29.2-54.2, p=0.063), low sensitive group (n=32, 37.5%, 90% CI; 26.0-53.6, p=0.1326), and visceral metastases (n=24, 48%, 90%CI; 28.2-60.3 p=0.072). The median PFS was 7.1 mo. (95% CI: 5.6-10.6). Conclusion:This study shows that 2nd line ETs was effective and might be a valid option in the sequence of treatments for postmenopausal women with ABC with low sensitivity to initial ET. It was suggested that PgR and visceral metastasis were significant predictive factors for CBR.
Citation Format: Araki K, Fujisawa T, Sakamaki K, Kikawa Y, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N. Sequential second line endocrine therapy is still an effective strategy for postmenopausal ER+ and HER2- advanced breast cancer with low sensitivity to initial endocrine therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-13-09.
Collapse
Affiliation(s)
- K Araki
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Fujisawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - K Sakamaki
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - Y Kikawa
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Iwamoto
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Sangai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Shien
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - S Takao
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - R Nishimura
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - M Takahashi
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Aihara
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - H Mukai
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - N Taira
- Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; Okayama University Hospital, Okayama, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan; Breast Center, Aihara Hospital, Minoh, Osaka, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; Gunma Prefectural Cancer Center, Otha, Gunma, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Chiba University Graduate School of Medicine, Chiba, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan
| |
Collapse
|
8
|
Mori H, Kubo M, Kai M, Kurata K, Kawaji H, Kaneshiro K, Motoyama Y, Kuroki R, Yamada M, Nishimura R, Okido M, Oda Y, Nakamura M. Abstract P4-06-22: Transcription factor T-bet and PD-L1 expression in tumor microenvironment of triple-negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-06-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Many analyzes regarding immunotherapies using checkpoint blockade has made it clear that tumor infiltrating lymphocytes (TILs) plays an important role in treating cancers with high levels of somatic mutations such as triple-negative breast cancer (TNBC). We reported the relationship between TILs and PD-L1 expression, and revealed that high-TILs/positive-PD-L1 expression population in TNBC was associated with better prognosis (Oncotarget 2017). However, its molecular mechanism is still unclear. Meanwhile, T-box transcription factor 21 (T-bet) which regulates effecter T-cells activation is derived by stimulation of T-cell receptor and IL-12. Activated T-cells work as antitumor lymphocytes by enhancing the production of cytokines such as INFγ. We focused on T-bet and examined the function of activated T-cells.
Patients and Methods: This study included 242 patients with primary TNBC who underwent resection without neoadjuvant chemotherapy at our three hospitals between January 2004 and December 2014. The immunohistochemistry scoring for CD8 and T-bet expression on TILs was defined as ≥30 per 0.00625mm2. PD-L1 positivity was defined as ≥1% of tumor cells staining positive for PD-L1.
Results: Of the 242 TNBC, CD8 on TILs was expressed as positive in 127 (52.5%) tumors, T-bet on TILs was expressed as positive in 67 (27.7%) tumors, and PD-L1 expression on tumor cells was expressed as positive in 99 (40.9%) tumors. T-bet expression was significantly correlated with CD8 expression (P<0.0001) and PD-L1 expression (P=0.0004). There was no significant difference in recurrence free survival (RFS) and overall survival (OS) regardless of CD8 or PD-L1expression level. Meanwhile, the patients with T-bet-positive tumors had a longer OS, compared to those with T-bet-negative tumors (P = 0.13 in RFS and P = 0.047 in OS). The multivariate analysis revealed that T-bet expression on TILswas an independent and positive prognostic factor for OS(HR = 0.5, 95%CI 0.1-0.9, P = 0.035).
Conclusion: OS was significantly longer among patients with high T-bet expressing TNBC. These results may validate the significance of T-bet as a biomarker for various immunotherapies in TNBC.
Citation Format: Mori H, Kubo M, Kai M, Kurata K, Kawaji H, Kaneshiro K, Motoyama Y, Kuroki R, Yamada M, Nishimura R, Okido M, Oda Y, Nakamura M. Transcription factor T-bet and PD-L1 expression in tumor microenvironment of triple-negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-22.
Collapse
Affiliation(s)
- H Mori
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Kubo
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Kai
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - K Kurata
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - H Kawaji
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - K Kaneshiro
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - Y Motoyama
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - R Kuroki
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Yamada
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - R Nishimura
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Okido
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - Y Oda
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Nakamura
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| |
Collapse
|
9
|
Arima N, Nishimura R, Osako T, Okumura Y, Nakano M, Fujisue M. Abstract P5-05-11: Clinical significance of androgen receptor expression in breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-05-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Breast cancer is highly heterogeneous and immunohistochemistry (IHC) is used to determine breast cancer subtypes using estrogen and progesterone receptor (ER and PgR), HER2 and Ki-67. The androgen receptor (AR) is frequently expressed in breast cancer, but evaluation of AR has not been standardized and the oncogenic activity in breast cancer is still unclear. The objectives of this study were to assess the clinical significance of AR expression in breast cancer patients with primary (pretreatment and posttreatment) and recurrent breast cancer in relation to breast cancer subtype.
Methods
Primary and recurrent breast cancer patients who underwent treatment from March 2017 to May 2018 were enrolled in this study. A total of 591 primary breast cancer cases and 52 recurrent cases were analyzed. Thirty-four primary cases received treatment before surgery. The factors investigated included nodal status, tumor size, nuclear grade, ER/PgR and HER2 status, p53 overexpression, and the Ki-67 index value. The AR expression was evaluated using IHC and the expression was divided into 3 groups; negative, low (<10%) and high (≥10%). Breast cancer subtypes were categorized based on the IHC data derived from ER/PgR, HER2 and Ki-67 (cutoff point: 20%) in invasive tumors.
Results
The AR expression rates were 69.7%(low: 33.9% and high: 35.8%)in all primary cases. Patients who received treatment before surgery had an AR rate of 38.2% which was significantly different from the untreated cases (p=0.002). In the cases with neoadjuvant chemotherapy, the positive rate significantly decreased after chemotherapy in the cases with non-pCR (pathological complete response). The positive rate of recurrent/metastatic cases was 57.7% (low: 34.6% and high: 23.1%). Higher AR expression significantly correlated with smaller tumor size, positive ER/PgR, lower Ki-67 values and nuclear grade and negative p53 overexpression. The AR expression rate was 72.5% in Luminal A, 73.2% in Luminal B, 80% in Luminal HER2, 56.8% in HER2 enriched and 43.5% in triple negative (TN) cases. Moreover, in the TN tumor cases, AR expression significantly correlated with postmenopausal status and a higher degree of malignancy determined by Ki-67, p53, and nuclear grade. However, there was no significant relationship between these factors and the other subtypes.
Conclusion
The AR expressions were higher in the primary breast cancer cases than in the pretreated and recurrent cases. The AR expression significantly correlated with a lower degree of malignancy and postmenopausal status only in the TN breast cancer cases. These findings suggest that the TN cases with AR-positive tumors have a more favorable prognosis compared with the cases with AR-negative tumors. However, further studies are needed to determine the predictive and prognostic factors for clinical use.
Citation Format: Arima N, Nishimura R, Osako T, Okumura Y, Nakano M, Fujisue M. Clinical significance of androgen receptor expression in breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-05-11.
Collapse
Affiliation(s)
- N Arima
- Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - R Nishimura
- Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - T Osako
- Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - Y Okumura
- Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - M Nakano
- Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - M Fujisue
- Kumamoto Shinto General Hospital, Kumamoto, Japan
| |
Collapse
|
10
|
kazuhiro S, Sugiyama K, Nozawa K, Funahashi Y, Kogure Y, Kitagawa C, Ichihara S, Nishimura R, Kubota T, Saka H. Single-institute, retrospective study of metastatic uveal melanoma in the immune check point inhibitor era. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy439.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Nishimura R, Yamamoto Y, Narui K, Kijima Y, Hozumi Y, Ikeda M, Takao S, Ohtani S, Iwase H. Abstract P3-11-02: A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: After the failure of a non-steroidal aromatase inhibitor (nsAI) for postmenopausal patients with advanced/metastatic breast cancer (BC), it is unclear which of the various kinds of endocrine monotherapy is the most appropriate. In a previous report it was found that toremifene 120 mg (TOR 120), a selective estrogen receptor modulator (SREM), was superior to steroidal AI in terms of progression-free survival after ns-AI in the Hi-FAIR ex trial. A phase II randomized trial of TOR 120 versus fulvestrant 500 mg (FUL 500), a selective estrogen receptor down regulator (SERD), was also conducted to select the most promising endocrine monotherapy after ns-AI in advanced/metastatic BC(Study registry number: UMIN000010087).
Patients and Methods: Postmenopausal women (n=106) with advanced/metastatic hormone-receptor positive BC from October 2011 to September 2014 were enrolled in this study. Fifty-three of the patients were randomly assigned to the TOR 120 (120 mg daily p.) group and 53 of the patients were randomly assigned to the FUL 500 group. In the FUL 500 group they were administered 500 mg of fulvestrant intramuscularly (im) on day 0, then 500 mg im on days 14 and 28 and every 28 days thereafter). If treatment failure occurred in either of the randomly assigned groups the patients were then removed and treated accordingly. A full analysis set was targeted for all cases that received the protocol treatment even once (TOR 120 (n=53) and FUL 500 (n=52)). The primary end point was the clinical benefit rate (CBR). The secondary end points were the objective response rate (ORR), progression-free survival (PFS), time to chemotherapy (TTCT), overall survival (OS), toxicity, and CBR, ORR and PFS after crossover of non-assigned treatment.
Results: A median follow up period of 30 months revealed that the CBR of FUL 500 (57.7%) tended to be superior to the CBR of TOR 120 (45.3%), the odds ratio (OR) was 1.70 (95% CI 0.74–3.62), and the median PFS was 7.8 months in the FUL 500 group and 5.8 months in the TOR 120 group. Moreover the hazard ratio (HR) was 0.79 (95% CI 0.52–1.21). However, there was no difference between the two groups in terms of ORR (17.7% and 15.1%, respectively), TTCT (13.3 months vs. 17.7 months, HR = 0.94 (95%CI 0.57 – 1.53)), and OS (33.4 months vs. not reached HR 1.29; 95% CI 0.80–2.09). At the cross-over phase, 33 and 24 patients after failure of assigned treatment were treated with FUL 500 and TOR 120, respectively. The CBR and PFS of FUL 500 after TOR 120 was better than that of TOR 120 after FUL 500 (CBR; 42.4% vs. 20.8%, OR = 0.33, 95%CI 0.09 – 1.11, median PFS; 6.2 months vs. 3.4 months; HR = 1.95, 95%CI 1.08–3.51). No difference between the two groups was observed in PFS from randomization to the end of the crossover phase. Moreover, there were few severe adverse events in either of the two groups.
Conclusions: FUL 500 used as a subsequent endocrine therapy for advanced/metastatic BC patients who failed ns-AI could potentially be more effective than TOR 120. However, the efficacy of SERM after failure of FUL 500 may be limited.
Citation Format: Nishimura R, Yamamoto Y, Narui K, Kijima Y, Hozumi Y, Ikeda M, Takao S, Ohtani S, Iwase H. A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-11-02.
Collapse
Affiliation(s)
- R Nishimura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Yokohama City University, Yokohama, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University/Ibaraki Prefectural Central Hospital, Kasama, Japan; Fukuyama City Hospital, Fukuyama, Japan; Hyogo Cancer Center, Akashi, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Y Yamamoto
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Yokohama City University, Yokohama, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University/Ibaraki Prefectural Central Hospital, Kasama, Japan; Fukuyama City Hospital, Fukuyama, Japan; Hyogo Cancer Center, Akashi, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - K Narui
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Yokohama City University, Yokohama, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University/Ibaraki Prefectural Central Hospital, Kasama, Japan; Fukuyama City Hospital, Fukuyama, Japan; Hyogo Cancer Center, Akashi, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Y Kijima
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Yokohama City University, Yokohama, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University/Ibaraki Prefectural Central Hospital, Kasama, Japan; Fukuyama City Hospital, Fukuyama, Japan; Hyogo Cancer Center, Akashi, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Y Hozumi
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Yokohama City University, Yokohama, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University/Ibaraki Prefectural Central Hospital, Kasama, Japan; Fukuyama City Hospital, Fukuyama, Japan; Hyogo Cancer Center, Akashi, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - M Ikeda
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Yokohama City University, Yokohama, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University/Ibaraki Prefectural Central Hospital, Kasama, Japan; Fukuyama City Hospital, Fukuyama, Japan; Hyogo Cancer Center, Akashi, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - S Takao
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Yokohama City University, Yokohama, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University/Ibaraki Prefectural Central Hospital, Kasama, Japan; Fukuyama City Hospital, Fukuyama, Japan; Hyogo Cancer Center, Akashi, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - S Ohtani
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Yokohama City University, Yokohama, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University/Ibaraki Prefectural Central Hospital, Kasama, Japan; Fukuyama City Hospital, Fukuyama, Japan; Hyogo Cancer Center, Akashi, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - H Iwase
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Yokohama City University, Yokohama, Japan; Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ibaraki Clinical Education and Training Center, Faculty of Medicine, Tsukuba University/Ibaraki Prefectural Central Hospital, Kasama, Japan; Fukuyama City Hospital, Fukuyama, Japan; Hyogo Cancer Center, Akashi, Japan; Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| |
Collapse
|
12
|
Arima N, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Fujisue M, Toyozumi Y. Abstract P2-09-32: Ki-67 index value and progesterone receptor status predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor positive and HER2 negative tumors. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-09-32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer is no longer a single disease with high molecular heterogeneity. Gene profiling has identified at least 4 subtypes: Luminal A, Luminal B, HER2-enriched and basal-like breast cancer. Moreover, immunohistochemistry (IHC) classification is now considered a surrogate for establishing breast cancer subtypes. In previous report Luminal A was defined as ER and PgR positive, HER2 negative, Ki-67 low and recurrence risk low based on the multi-gene-expression assay. The distinction between Luminal A-like and Luminal B-like can be made by either using a high Ki-67 value (≥20%) or a low PgR value (< 20%). In this study, patients with ER positive, HER2 negative and negative node were classified into 4 groups according to the PgR and the Ki-67 status (cutoff points: 20%) and examined retrospectively in relation to clinicopathological findings including the recurrence score (RS) and disease-free survival (DFS).
Methods: A total of 1866 invasive breast cancer patients from November 2001 to November 2016 were included in this study. The cases were classified as follows; LA as high PgR/low Ki-67 (850 cases), LB1 as high PgR/high Ki-67 (553 cases), LB2 as low PgR/high Ki-67 (226 cases), and LB3 as low PgR/low Ki-67 (237 cases). Out of all these cases, 1510 were treated with endocrine therapy alone. The median follow-up period was 78.1 months. Moreover, 23 of the cases underwent a 21-gene expression assay and the RS (< 25 and > 26) was compared with our classification.
Results: The median age was 57.4 years (range: 25 - 94). T1 tumors were more common in the LA group and rare in the LB2 group. Nuclear grade 3 and p53 overexpression were significantly correlated with LB2. Endocrine therapy alone was performed in 87.4% (LA), 77.4% (LB1), 58.8% (LB2) and 86.9% (LB3), retrospectively. There were significant differences in DFS between the LA group (5y DFS: 98%, 10 y DFS: 95.9%) and the LB2 group (5y: 89.9%, 10y: 83.6%; p<0.0001) or LB1 (5y: 94.9%, 10y: 89.5%; p<0.0001), but there was no difference with the LB3 group (5y: 98.6%, 10y: 94.7%; p=0.88). In the cases with endocrine therapy alone, LA showed a similar DFS with LB3 (p=0.25). LB2 had a significantly worse DFS in all the cases and in the cases with endocrine therapy. Chemotherapy was administered to cases with a higher nuclear grade in combination with endocrine therapy. In the LB2 group, there was no difference in DFS between the cases with endocrine therapy and in the cases with chemo-endocrine therapy. Moreover, most of the cases with LA (1/1) and LB1 (15/16) had a RS of <25, and all of the LB2 (6/6) cases had a RS of >26.
Conclusion: The patients with LA and LB3 (both: Ki-67<20%) had a favorable DFS even in the endocrine therapy alone group. However, LB1 and LB2 (both: Ki-67≥20%) had a poorer DFS. Moreover, LB2 (PgR<20% and Ki-67≥20%) was significantly correlated with a higher degree of malignancy and benefited from chemotherapy. LA and LB3 with low Ki-67 values were considered to be a part of the Luminal A group. These data suggest that PgR and the Ki-67 status are useful in predicting prognosis and deciding the treatment strategy for patients with ER-positive and HER2 negative breast cancer.
Citation Format: Arima N, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Fujisue M, Toyozumi Y. Ki-67 index value and progesterone receptor status predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor positive and HER2 negative tumors [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-09-32.
Collapse
Affiliation(s)
- N Arima
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - R Nishimura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - T Osako
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - Y Nishiyama
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - Y Okumura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - M Fujisue
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - Y Toyozumi
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| |
Collapse
|
13
|
Ochiai H, Shirasawa T, Nanri H, Nishimura R, Hoshino H, Kokaze A. Influence of eating quickly and eating until full on anthropometric gains in girls: A population-based, longitudinal study. Child Care Health Dev 2017; 43:918-925. [PMID: 28612455 DOI: 10.1111/cch.12482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 04/16/2017] [Accepted: 05/21/2017] [Indexed: 11/29/2022]
Abstract
BACKGROUND In examining childhood overweight/obesity, there is a need to consider both eating quickly and eating until full. This longitudinal study investigated the influence of eating quickly and/or eating until full on anthropometric variables and becoming overweight/obese among Japanese schoolgirls. METHODS Study participants were fourth-grade schoolgirls (aged 9 or 10 years) in Ina Town, Japan. Physical examinations and a questionnaire survey were performed at baseline (fourth grade) and after 3 years (seventh grade). Height, weight, and waist circumference were measured in the physical examinations, while the data on eating quickly and eating until full were collected in the questionnaire survey. Analysis of variance and analysis of covariance were used to compare the differences in each anthropometric variable between fourth and seventh grade among groups. RESULTS Data on 425 non-overweight/obese schoolgirls in fourth grade were analyzed. Gains in anthropometric variables (body mass index, waist circumference, and waist-to-height ratio) from fourth to seventh grade were significantly larger in the "eating quickly and eating until full" group than in the "not eating quickly and not eating until full" group. In contrast, there were no significant differences in the gains between the "eating quickly or eating until full" group and the "not eating quickly and not eating until full" group. The proportion of overweight/obese girls in seventh grade was higher in the "eating quickly and eating until full" group than in the other groups. CONCLUSIONS Eating quickly and eating until full had a substantial impact on excess gains in anthropometric variables among schoolgirls, suggesting that modifying these eating behaviors may help prevent non-overweight/obese girls from the excess gains. Accordingly, school health programs need to focus on not eating quickly and/or not eating until full to prevent overweight/obesity; it is necessary to emphasize "the risk of overweight/obesity associated with these eating behaviors" in schools.
Collapse
Affiliation(s)
- H Ochiai
- Department of Public Health, Showa University School of Medicine, Tokyo, Japan
| | - T Shirasawa
- Department of Public Health, Showa University School of Medicine, Tokyo, Japan
| | - H Nanri
- Department of Public Health, Showa University School of Medicine, Tokyo, Japan
| | - R Nishimura
- Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
| | - H Hoshino
- Department of Public Health, Showa University School of Medicine, Tokyo, Japan
| | - A Kokaze
- Department of Public Health, Showa University School of Medicine, Tokyo, Japan
| |
Collapse
|
14
|
Ong SM, Saeki K, Kok MK, Tanaka Y, Choisunirachon N, Yoshitake R, Nishimura R, Nakagawa T. Anti-tumour efficacy of etoposide alone and in combination with piroxicam against canine osteosarcoma in a xenograft model. Res Vet Sci 2017; 113:130-135. [PMID: 28957780 DOI: 10.1016/j.rvsc.2017.09.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 09/14/2017] [Accepted: 09/16/2017] [Indexed: 12/21/2022]
Abstract
Osteosarcoma (OSA) in dogs is locally invasive and highly malignant. Distant metastasis is the most common cause of death. To date, the survival rate in dogs with OSA remains poor. The cytotoxic effects of etoposide against canine OSA cell lines, either alone or in combination with piroxicam, have been previously demonstrated in vitro. The aim of this study was to evaluate the anti-tumour effect of etoposide alone and in combination with piroxicam on canine OSA using murine models. Etoposide single agent treatment significantly delayed tumour progression with a marked reduction in Ki-67 immunoreactivity in tumour tissue. Concomitant treatment with piroxicam did not enhance the anti-tumour efficacy of etoposide. Etoposide single agent treatment and combination treatment with piroxicam down-regulated survivin expression, but was not followed by increased apoptotic activity. These findings indicate that etoposide might be a promising novel therapeutic for canine OSA. Further investigations into its potential for clinical application in veterinary oncology are warranted.
Collapse
Affiliation(s)
- S M Ong
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - K Saeki
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| | - M K Kok
- Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - Y Tanaka
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - N Choisunirachon
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| | - R Yoshitake
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - R Nishimura
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| | - T Nakagawa
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| |
Collapse
|
15
|
Maor E, Raphael C, Panaich S, Alkhouli M, Cabalka A, Hagler D, Pollak P, Reeder G, Nishimura R, Eleid M, Rihal C. 4800Left atrial hemodynamics during percutaneous mitral paravalvular leak closure are associated with long term survival. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.4800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Arima N, Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Koga T, Kurashita K, Todoroki H, Ueo H, Ohi Y, Toyoshima S, Mitsuyama S, Tamura K. Abstract P4-21-25: The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Anti-HER2 treatment using trastuzumab (Tmab) has contributed to improving the clinical outcome of HER2-positive breast cancerpatients. However, some patients do not respond to Tmab therapy and the combination of Lapatinib and capecitabine (LC) is an effective treatment option after progression on Tmab. Hormone receptor status is also an important factor for deciding if the patient should be treated with endocrine therapy as well. The aim of this study was to investigate the clinical significance of hormone receptor status in biomarker expression and to evaluate the efficacy of lapatinib therapy.
Materials and Methods: Eighty patients with HER2 positive breast cancer refractory to Tmab were enrolled in this prospective trial (KBC-SG 1107) between December 2011 and March 2014. The following treatment began after enrollment; lapatinib 1250-mg tablets were administered orally once daily and capecitabine (2000 mg/m2 per day) on days 1 to 14 every 21 days until disease progression or until severe adverse events. Total HER2 (H2T), p95HER2 (p95), and total HER3 (H3T) expression levels were quantified in formalin-fixed paraffin embedded samples using VeraTag assays. ER and progesterone receptor (PgR), PTEN and p95 expressions were evaluated using immunohistochemistry (IHC) and PIK3CA mutation using direct sequencing. Statistical analyses were performed using SPSS (ver. 21). A two-sided P<0.05 was considered a statistically significant difference.
Results: The ER- and PgR-positive rates were 55.0% and 33.8%, respectively. The response rate to LC was 30% (CR: 1 case; PR: 23 cases), the clinical benefit rate was 51.3% and the median progression-free survival (PFS) was 174.5 days. Both ER and PgR negativity significantly correlated with higher H2T (cutoff: 13.8), p95HER2 (cutoff: 2.8) and PTEN expression levels (cutoff: H score of 100). Lower H2T expression levels and PIK3CA mutation rates were often observed in the non-responders (both: p=0.087). The ER and PgR status did not correlate with response. A high p95 and PTEN expression significantly correlated with longer PFS in ER and/or PgR positive cases (p=0.02 and 0.03), respectively. The overall survival (OS) after LC significantly correlated with the number of recurrence organs (p=0.0002) but not with the p95 and PTEN expression levels.
Conclusion: LC therapy was effective in Tmab-refractory HER2 positive breast cancer. Moreover, the biomarker expression differed depending on the ER/PgR status and a high p95 and PTEN expression correlated with longer PFS in ER and/or PgR positive cases. Further study is necessary to validate these findings.
Citation Format: Arima N, Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Koga T, Kurashita K, Todoroki H, Ueo H, Ohi Y, Toyoshima S, Mitsuyama S, Tamura K. The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-25.
Collapse
Affiliation(s)
- N Arima
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - R Nishimura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - U Toh
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - M Tanaka
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - M Saimura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - Y Okumura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - T Saito
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - T Tanaka
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - M Teraoka
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - K Shimada
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - T Koga
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - K Kurashita
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - H Todoroki
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - H Ueo
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - Y Ohi
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - S Toyoshima
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - S Mitsuyama
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - K Tamura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| |
Collapse
|
17
|
Mori H, Kubo M, Yamaguti R, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Oda Y, Nakamura M. Abstract P6-07-05: PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor microenvironment has been considered to have an active role in determining the aggressiveness of tumor cells. Recently, programmed cell death ligand-1 (PD-L1) expression or tumor-infiltrating lymphocytes (TILs) are known to be an important prognostic factor of breast cancer. However, the correlation of expression of PD-L1 and TILs still remains unclear. Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses. Further identification of these subclasses is necessary in order to predict prognosis and choose appropriate treatments. Our goal was to correlate PD-L1 expression with clinicopathological features including TILs by using a large cohort of TNBCs.
Patients and Methods: This study included 248 patients with primary TNBC who underwent resection without neoadjuvant chemotherapy at our three hospitals between January 2004 and December 2014. The tumor subtypes were routinely determined immunohistochemically by using resected specimens. IHC scoring for PD-L1 expression was defined in reference to that for HER2 expression. PD-L1 positivity was defined as both IHC 2+ and IHC 3+. Cases were defined as high if stromal TILs ≥50% according to recommendations by the International TILs Working Group.
Results: Of the 248 TNBCs, PD-L1 were expressed as positive in 103 (41.5%) tumors, and TILs were highly present in 118 (47.6%) tumors. PD-L1 expression was significantly correlated with higher levels of TILs (P < 0.0001). There was no significant difference when the prognosis of the patients who had PD-L1-positive tumors was compared with that of the patients who had PD-L1-negative tumors (P = 0.56 in recurrence free survival [RFS] and P = 0.13 in overall survival [OS]). Meanwhile, the patients with high-TILs tumors had longer OS, compared to the patients with low-TILs tumors (P = 0.55 in RFS and P = 0.016 in OS). The analysis in the cross effect between PD-L1 expression and TILs using cox proportional hazards model demonstrated that the PD-L1 expression and TILs are not independent factors(P = 0.0018 in RFS and P = 0.015 in OS). The PD-L1-positive group with low-TILs had significantly shorter survival than the PD-L1-positive group with high-TILs (hazard ratio [HR] = 4.7, 95% confidence interval [CI] 1.6–12.7, P = 0.0067 in RFS; HR = 8.4, 95%CI 2.3-30.3, P = 0.0019 in OS).
Conclusions: Our data indicated that PD-L1 expression was related to higher levels of TILs, and PD-L1-positive tumors with low-TILs were associated with poor prognosis in patients with TNBCs. It is proposed that these biomarkers may be of use for predicting their prognosis and essential in the subclassification of TNBCs.
Citation Format: Mori H, Kubo M, Yamaguti R, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Oda Y, Nakamura M. PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-05.
Collapse
Affiliation(s)
- H Mori
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Kubo
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - R Yamaguti
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - R Nishimura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - T Osako
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - N Arima
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - Y Okumura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Okido
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Yamada
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Kai
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - J Kishimoto
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - Y Oda
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Nakamura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| |
Collapse
|
18
|
Iizuka T, Masui K, Miyabe-Nishiwaki T, Kanazawa H, Nishimura R. Propofol-fentanyl interaction in Beagles - Apnea, response to mechanical ventilation, endotracheal tube, and tetanic stimulation. Res Vet Sci 2017; 115:34-42. [PMID: 28152385 DOI: 10.1016/j.rvsc.2017.01.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Revised: 11/28/2016] [Accepted: 01/20/2017] [Indexed: 12/25/2022]
Abstract
The objective of this study was to characterize the propofol-fentanyl interaction in Beagles for four pharmacodynamic endpoints: apnea, response to mechanical ventilation, endotracheal tube, and tetanic stimulation. After anesthesia was induced with varying combinations of propofol and fentanyl, the pharmacodynamic endpoints were assessed in intubated dogs (n=6) using the cross-over design. Effective concentrations of propofol plasma concentration (Cp) and fentanyl Cp were assessed using additive, reduced Greco, Minto, and hierarchical interaction models. The interaction was best described as synergistic by the hierarchical model. A 1ng/mL fentanyl Cp reduced the effective propofol Cp to half or less of that without fentanyl for all endpoints. An additional increment of fentanyl Cp to 5ng/mL or higher hardly reduced effective propofol Cp for all endpoints except response to tetanic stimulation. Additionally, the effective propofol Cp in 50% dogs for response to tetanic stimulation (15% increase of heart rate) was lower than that for the other endpoints at fentanyl Cp >7ng/mL. Peripheral oxygen saturation decreased below 90% after extubation in five treatments in which fentanyl Cps were ≥5ng/mL. Propofol and fentanyl interacted synergistically. To avoid patient-ventilator dyssynchrony and hypoxemia after extubation, fentanyl Cp at 1-5ng/mL may be appropriate in intubated dogs. When a dog responds to mechanical ventilation or endotracheal tube at a high fentanyl Cp >5ng/mL under propofol anesthesia even if the dog tolerate to tetanic stimulation, it may be necessary to increase propofol Cp to eliminate the responses because an additional fentanyl may be little impact.
Collapse
Affiliation(s)
- T Iizuka
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - K Masui
- Department of Anesthesiology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
| | - T Miyabe-Nishiwaki
- Center of Human Evolution Modeling Research, Primate Research Institute, Kyoto University, Inuyama, Aichi 484-8506, Japan
| | - H Kanazawa
- Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan
| | - R Nishimura
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| |
Collapse
|
19
|
Ong SM, Saeki K, Tanaka Y, Nishimura R, Nakagawa T. Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines. Vet J 2016; 218:51-59. [PMID: 27938709 DOI: 10.1016/j.tvjl.2016.11.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2016] [Revised: 09/21/2016] [Accepted: 11/15/2016] [Indexed: 12/21/2022]
Abstract
Osteosarcoma (OSA) is the most common primary bone tumour in dogs. The poor survival rate in dogs with OSA highlights the need for new therapeutic approaches. This study evaluated the cytotoxic effects of etoposide, alone and in combination with piroxicam, on canine OSA cell cultures. Etoposide alone significantly suppressed cell growth and viability, whereas etoposide in combination with piroxicam exhibited concentration dependent cytotoxicity. The anti-proliferative effect was a result of inactivity of the Cdc2-cyclin B1 complex, which correlated with an increase in the G2/M fraction. This subsequently activated the apoptosis cascade, as indicated by elevated apoptosis levels and up-regulation of poly (ADP-ribose) polymerase proteolytic cleavage. Down-regulation of survivin expression induced by the combination treatment may have contributed to the enhanced cytotoxicity. The results of this study suggest that further investigation of etoposide and piroxicam as a therapeutic combination for canine OSA is warranted.
Collapse
Affiliation(s)
- S M Ong
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - K Saeki
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - Y Tanaka
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - R Nishimura
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - T Nakagawa
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| |
Collapse
|
20
|
Abstract
CT, MR and angiographic findings of 6 patients with 9 skull metastases from hepatocellular carcinoma (HCC) were reviewed. In 3 of 6 patients, local pain or neurologic deficit was the initial main manifestation of the disease, although all had been treated for chronic liver disease. In the remaining 3 patients, skull metastases were detected following treatment of HCC. The metastatic lesions appeared as expansile osteolytic masses on CT and as hypervascular masses on angiography. All lesions were demonstrated on MR imaging. Compared with the brain parenchyma, the lesions were iso- or hypointense on T1-weighted and T2-weighted MR images. The lesions were moderately to markedly enhanced by Gd-DTPA. Flow voids were shown in the tumors in 5 lesions. HCC should be included in the differential diagnosis of an osteolytic hypervascular lesion of the skull, especially in Oriental patients. The relatively hypointense tumor on T2-weighted MR images associated with flow void, different from primary skull tumors or directly invasive tumors, may support the diagnosis of HCC metastasis.
Collapse
Affiliation(s)
- R. Murakami
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - Y. Korogi
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - Y. Sakamoto
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - M. Takahashi
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - T. Okuda
- Department of Radiology, Kumamoto City Hospital, Kumamoto, Japan
| | - T. Yasunaga
- Department of Radiology, Kumamoto City Hospital, Kumamoto, Japan
| | - R. Nishimura
- Department of Radiology, National Saishunso Hospital, Kumamoto, Japan
| | - S. Yoshimatsu
- Department of Radiology, Kumamoto Regional Medical Center, Kumamoto, Japan
| |
Collapse
|
21
|
Murakami R, Baba Y, Furusawa M, Nishimura R, Nakaura T, Baba T, Katsura F, Eura M, Masuyama K, Takahashi M. Early glottic squamous cell carcinoma: Predictive value of MR imaging for the rate of 5-year local control with radiation therapy. Acta Radiol 2016. [DOI: 10.1258/rsmacta.41.1.38] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Purpose: To evaluate MR findings in early (T1 and T2 stages) glottic carcinomas and the predictive value of MR imaging for the rate of 5-year local control with radiation therapy. Material and Methods: Eighty-three patients with early glottic carcinomas were prospectively examined with MR at 1.5 T. MR investigation included unenhanced T1-weighted, T2-weighted, dynamic and contrast-enhanced T1-weighted images. Three patients with presumed advanced diseases on MR were initially treated with total laryngectomy and were excluded from the study. The remaining 80 patients were treated with radiation therapy with curative intent. Tumor detectability, size and relationship to the thyroid cartilage were determined on MR images. The MR findings were then correlated with the rate of local control. Results: Forty-eight of 80 lesions (60%) were detected on MR imaging. All detected lesions but 1 demonstrated increased signal on T2-weighted images. The lesions were best delineated on dynamic images (statistically significant). The 5-year local control rate with radiation therapy was 72%. Univariate analysis revealed clinical T stage, MR detectability, tumor size and relationship to the thyroid cartilage as significant predictors. Multivariate analysis revealed that the relationship to the thyroid cartilage was an independent factor. Conclusion: MR provides prognostic information about the results of definitive radiation therapy. To evaluate the tumor extension in lesions detected on precontrast MR images, contrast-enhanced dynamic images should be obtained.
Collapse
Affiliation(s)
- R. Murakami
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - Y. Baba
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - M. Furusawa
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - R. Nishimura
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - T. Nakaura
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - T. Baba
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - F. Katsura
- Department of Otorhinolaryngology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - M. Eura
- Department of Otorhinolaryngology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - K. Masuyama
- Department of Otorhinolaryngology, Kumamoto University School of Medicine, Kumamoto, Japan
| | - M. Takahashi
- Department of Radiology, Kumamoto University School of Medicine, Kumamoto, Japan
| |
Collapse
|
22
|
Nishimura R, Omiya H, Sugio K, Ubukata M, Sakai S, Samukawa Y. Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet. Diabetes Obes Metab 2016; 18:702-6. [PMID: 26639943 PMCID: PMC5066655 DOI: 10.1111/dom.12611] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 11/05/2015] [Accepted: 11/30/2015] [Indexed: 12/30/2022]
Abstract
This randomized, double-blind, placebo-controlled, crossover study was the first to determine the effects of luseogliflozin in combination with a low-carbohydrate diet (LCD) on 24-h glucose variability, assessed by continuous glucose monitoring (CGM). A total of 18 Japanese patients with type 2 diabetes were randomized into two groups, in which patients first received luseogliflozin 2.5 mg once daily then placebo for 8 days each, or vice versa. Patients took luseogliflozin or placebo with a normal-carbohydrate diet (NCD) on day 7 and with the LCD on day 8. CGM was performed on both days. Luseogliflozin significantly reduced glucose exposure in terms of the area under the curve over the course of 24 h when administered with the NCD (difference vs placebo: -555.6 mg/dl·h [1 mg/dl = 0.0556 mmol/l]; p < 0.001) or with the LCD (-660.7 mg/dl·h; p < 0.001). No hypoglycaemia was observed over 24 h with either diet. Although glucose levels were lower with the LCD than with the NCD in the placebo treatment period, luseogliflozin with the LCD improved glycaemic control throughout the day to nearly the same extent as luseogliflozin with the NCD, without inducing hypoglycaemia.
Collapse
Affiliation(s)
- R. Nishimura
- Division of Diabetes, Metabolism and Endocrinology, Department of Internal MedicineJikei University School of MedicineTokyoJapan
| | - H. Omiya
- Taisho Pharmaceutical Co., Ltd.TokyoJapan
| | - K. Sugio
- Taisho Pharmaceutical Co., Ltd.TokyoJapan
| | - M. Ubukata
- Taisho Pharmaceutical Co., Ltd.TokyoJapan
| | - S. Sakai
- Taisho Pharmaceutical Co., Ltd.TokyoJapan
| | | |
Collapse
|
23
|
Nagata T, Nakayama H, Uchida K, Uetsuka K, Yasoshima A, Yasunaga S, Masuda K, Tsujimoto H, Kuwajima E, Nishimura R, Sasaki N, Doi K. Two Cases of Feline Malignant Craniopharyngioma. Vet Pathol 2016; 42:663-5. [PMID: 16145213 DOI: 10.1354/vp.42-5-663] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Tumors at the cranial base in 2 cats (a 9 1/2-year-old, castrated male Chinchilla and a 7-year-old, castrated male American shorthair) were diagnosed as malignant craniopharyngioma. The tumor lesion was histopathologically divided into four parts: 1) a small acinus part, in which relatively large cells with a pale cytoplasm composed small acini; 2) a duct part, in which small cuboidal cells composed ducts; 3) a cyst part, in which there were large cysts lined with flat cells; and 4) a pavement part, in which large multiangular-shaped cells proliferated in a pavement pattern. The epithelial cells of some parts were positive for keratin by immunohistochemistry. Histopathologic findings of the present feline cases were identical to those of malignant craniopharyngioma in other animal species.
Collapse
Affiliation(s)
- T Nagata
- Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, 1-1-1 Yayoi, Bunkyoku, Tokyo 113-8657, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Tanabe M, Iwase T, Okumura Y, Yoshida A, Masuda N, Nakatsukasa K, Shien T, Tanaka S, Komoike Y, Taguchi T, Arima N, Nishimura R, Inaji H, Ishitobi M. Local recurrence risk after previous salvage mastectomy. Eur J Surg Oncol 2016; 42:980-5. [PMID: 27055945 DOI: 10.1016/j.ejso.2016.03.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2016] [Revised: 03/02/2016] [Accepted: 03/04/2016] [Indexed: 11/27/2022] Open
Abstract
INTRODUCTION Breast-conserving surgery is a standard treatment for early breast cancer. For ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery, salvage mastectomy is the current standard surgical procedure. However, it is not rare for patients with IBTR who have received salvage mastectomy to develop local recurrence. In this study, we examined the risk factors of local recurrence after salvage mastectomy for IBTR. PATIENTS AND METHODS A total of 118 consecutive patients who had histologically confirmed IBTR without distant metastases and underwent salvage mastectomy without irradiation for IBTR between 1989 and 2008 were included from eight institutions in Japan. The risk factors of local recurrence were assessed. RESULTS The median follow-up period from salvage mastectomy for IBTR was 4.6 years. Patients with pN2 or higher on diagnosis of the primary tumor showed significantly poorer local recurrence-free survival than those with pN0 or pN1 at primary tumor (p < 0.001). Multivariate analysis showed that the lymph node status of the primary tumor was a significantly independent predictive factor of local recurrence-free survival (p = 0.02). CONCLUSION The lymph node status of the primary tumor might be a predictive factor of local recurrence-free survival after salvage mastectomy for IBTR. Further research and validation studies are needed. (UMIN-CTR number UMIN000008136).
Collapse
Affiliation(s)
- M Tanabe
- Dept. of Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Iwase
- Dept. of Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Y Okumura
- Dept. of Breast & Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
| | - A Yoshida
- Dept. of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan
| | - N Masuda
- Dept. of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - K Nakatsukasa
- Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - T Shien
- Dept. of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan
| | - S Tanaka
- Section of Breast and Endocrine Surgery, Department of General and Gastroenterological Surgery, Osaka Medical College, Osaka, Japan
| | - Y Komoike
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - T Taguchi
- Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - N Arima
- Dept. of Pathology, Kumamoto City Hospital, Kumamoto, Japan
| | - R Nishimura
- Dept. of Breast & Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
| | - H Inaji
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - M Ishitobi
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
| | | |
Collapse
|
25
|
Mori H, Kubo M, Yamada M, Kai M, Osako T, Nishimura R, Arima N, Okido M, Kuroki S, Oda Y, Nakamura M. Abstract P4-09-15: BRCAness and PD-L1 expression of basal-like and not basal-like triple negative breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-09-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple Negative Breast Cancer (TNBC) subtype occurs in approximately 20% of all patients with breast cancer and is associated with rapid growth, early metastasis and poor prognosis compared with other subtypes. TNBCs are a heterogeneous disease entity and further subclassification is needed, but still ongoing. In this study, we assessed BRCAness, defined as shared characteristics between sporadic and BRCA1-mutated tumors, in a cohort of basal-like and non-basal-like TNBCs.
Patients and Methods: DNA was isolated from formalin-fixed paraffin-embedded tumor tissues and BRCAness status was analyzed in 262 patients with primary TNBCs resected at our three hospitals between 2004 and 2014. Classification of BRCAness was performed by using Multiple Ligation-dependent Probe Amplification (MLPA) with the probemix P376 BRCA1ness by MRC (Amsterdam, Holland). The tumor subtypes were routinely determined immunohistochemically by using resected specimens. Basal-like phenotype was defined as being positive for Epidermal Growth Factor Receptor (EGFR) and/or Cytokeratin 5/6 (CK5/6). Moreover, TNBCs were stained and analyzed for programmed cell death ligand-1 (PD-L1) expression as a target of new immune therapies.
Results: Of 262 TNBCs, 232 tumors (88.5%) was a basal-like phenotype. The results of MLPA assay showed that 159 (68.5%) of 232 tumors had a BRCAness profile. Patients with basal-like BRCAness tumors were younger than patients with basal-like non-BRCAness tumors (p<0.0001). There was no significant difference between the two groups regarding pathological stage. The basal-like BRCAness group had shorter relapse-free survival (RFS) and overall survival (OS) than the basal-like non-BRCAness group (p=0.028 and p=0.13, respectively), and anthracycline-based regimens provided greater benefit to the basal-like BRCAness group significantly (p=0.01 in RFS and p=0.007 in OS). PD-L1 was expressed in 71 (44.7%) of 159 basal-like TNBCs with BRCAness.
Conclusion: We reported the majority of basal-like TNBCs showed a BRCAness profile and PD-L1 expressed in approximately 50% of BRCAness tumors. It is known that about 30% of BRCAness tumors are BRCA1-mutated tumors. Those biomarkers are essential for subclassification of TNBCs and may offer not only platinum-based chemotherapy but also novel therapies, such as immune-targeted therapies of PD-1/PD-L1 inhibitors and PARP inhibitors, to patients with basal-like TNBCs with BRCAness.
Citation Format: Mori H, Kubo M, Yamada M, Kai M, Osako T, Nishimura R, Arima N, Okido M, Kuroki S, Oda Y, Nakamura M. BRCAness and PD-L1 expression of basal-like and not basal-like triple negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-09-15.
Collapse
Affiliation(s)
- H Mori
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Kubo
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Yamada
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Kai
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - T Osako
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - R Nishimura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - N Arima
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Okido
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - S Kuroki
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - Y Oda
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| | - M Nakamura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Kuroki Breast Clinic, Fukuoka City, Japan
| |
Collapse
|
26
|
Arima N, Nishimura R, Osako T, Nishiyama Y, Fujisue M, Okumura Y, Murakami K, Toyozumi Y. Abstract P4-09-26: The difference between metachronous and synchronous bilateral breast cancer in terms of clinical features and biology. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-09-26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
The recent diagnostic modality such as MRI can diagnose a tiny breast lesion even in healthy contralateral breasts. Recently, the rate of contralateral prophylactic mastectomy (CPM) is on the rise in the United States. In Japan, the CPM has been started for selected patients with a high risk. In this study, we divided bilateral breast cancers into the synchronous and the metachronous group and then compared the clinical features and biology.
Patients and Methods
Out of 216 bilateral breast cancer patients who underwent surgery between 1995 and March 2015, there were 101 synchronous breast cancer cases and 115 metachronous breast cancer cases (interval to the second tumor > 1 year). The items examined were age, tumor size, lymph nodal status, histological type, and biological markers (ER, PgR, HER2, p53 and Ki-67 index values) in the cases with paired data.
Results
1. The incidence of metachronous tumors was relatively stable at 2.1–2.7% throughout the period. On the other hand, the incidence of synchronous tumors has increased to 4.4% in the most recent 5-year period and the median interval was 7.1 years.
2. There was no difference in the tumor size of both tumors in the synchronous group, but the second tumor was significantly smaller than the first tumor in the metachronous group (2.2cm to 1.7cm). The node negative rates showed no difference between two groups.
3. The cases with DCIS were seen in 20% and 25% of the synchronous group and 12% and 16% of the metachronous group. Most of the patients (94.3%) with invasive cancer received systemic adjuvant therapy in the metachronous group.
4. The ER positive rates of both tumors were 87.1% and 88.1% in the synchronous group and 71.6% and 68.4% in the metachronous group, respectively. The concordance rates were higher in the synchronous group (p=0.02). Moreover, there was a significant difference in ER positive rates between the two groups (p=0.01) and the ER negative tumors were more frequent in the second tumor of the metachronous group. The PgR negative tumors increased in the second tumor of metachronous cases. The shorter the interval (< 5years), the more the ER positive rate decreased (p=0.002). However, the longer interval did not correlate with the change of receptor status.
5. The Ki-67 index values significantly increased in the second tumor of the metachronous group, especially in the cases with a shorter interval. However, there was no difference in the synchronous group. The p53 overexpression rates significantly increased in the cases with a shorter interval.
6. The postoperative prognosis for the first tumor did not differ in both groups.
Conclusion
The incidence of synchronous bilateral breast cancer cases have increased but have remained relatively stable in the metachronous group. The concordance rates of the ER, PgR, Ki-67 and p53 status were higher in the synchronous group but the cases with negative ER, negative PgR, higher Ki-67 values and positive p53 increased in the second tumor of the metachronous group. These findings suggest that adjuvant systemic therapy played a important role in the treatment of bilateral breast cancer but the secondary tumor was more aggressive in the metachronous cases.
Citation Format: Arima N, Nishimura R, Osako T, Nishiyama Y, Fujisue M, Okumura Y, Murakami K, Toyozumi Y. The difference between metachronous and synchronous bilateral breast cancer in terms of clinical features and biology. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-09-26.
Collapse
Affiliation(s)
- N Arima
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - R Nishimura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - T Osako
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - Y Nishiyama
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - M Fujisue
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - Y Okumura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - K Murakami
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| | - Y Toyozumi
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kumamoto City Hospital, Kumamoto, Japan
| |
Collapse
|
27
|
Chambers JK, Yoshino Y, Fujiwara R, Nishimura R, Nakayama H, Uchida K. Thymic Carcinoma with Cartilage Formation in a Dog. J Comp Pathol 2016; 154:38-41. [PMID: 26781228 DOI: 10.1016/j.jcpa.2015.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Revised: 10/26/2015] [Accepted: 11/02/2015] [Indexed: 11/17/2022]
Abstract
An 11-year-old female Chihuahua exhibited respiratory distress and a computed tomography scan showed a large mass in the anterior thoracic cavity. During surgery, it was found that the mass was strongly adherent to surrounding tissue. A histopathological examination of a biopsy sample from the mass revealed proliferation of atypical epithelial cells and cartilage formation admixed with mature lymphocytes. Immunohistochemically, the tumour cells, as well as the normal canine thymic epithelial cells, were positive for pan-cytokeratin (CK), CK5/6, CK19, p63 and bone morphogenetic protein (BMP) 6. Foci of cartilage tissue were formed in association with the neoplastic epithelial tissue. In the normal canine thymus, the subcapsular epithelial cells are positive for both CK19 and BMP6. These findings indicate that the cartilage element within the tumour developed from CK19-positive neoplastic epithelial cells, which were derived from the thymic subcapsular epithelium. This case represents a novel variant of canine thymic epithelial tumour that exhibits cartilage differentiation.
Collapse
Affiliation(s)
- J K Chambers
- Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo, Japan
| | - Y Yoshino
- Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo, Japan
| | - R Fujiwara
- Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo, Japan
| | - R Nishimura
- Department of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo, Japan
| | - H Nakayama
- Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo, Japan
| | - K Uchida
- Department of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo, Japan.
| |
Collapse
|
28
|
Ohno H, Nishimura N, Yamada K, Shimizu Y, Nishimura R, Iwase S, Sugenoya J, Sato M. Water nanodroplets emitted from an air conditioner increased skin moisture levels at the lateral canthus in winter by forming a lipid film with sebum. Skin Res Technol 2015; 22:388-90. [PMID: 26343808 DOI: 10.1111/srt.12262] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/29/2015] [Indexed: 11/28/2022]
Affiliation(s)
- H Ohno
- The Department of Physiology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan
| | - N Nishimura
- The Department of Physiology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan
| | - K Yamada
- Hitachi Appliances, Inc., Tokyo, Japan
| | - Y Shimizu
- The Department of Physiology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan
| | - R Nishimura
- The Department of Physiology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan
| | - S Iwase
- The Department of Physiology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan
| | - J Sugenoya
- The Department of Physiology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan
| | - M Sato
- The Department of Physiology, School of Medicine, Aichi Medical University, Nagakute, Aichi, Japan
| |
Collapse
|
29
|
Nishimura R, Osonoi T, Kanada S, Jinnouchi H, Sugio K, Omiya H, Ubukata M, Sakai S, Samukawa Y. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study. Diabetes Obes Metab 2015; 17:800-4. [PMID: 25930989 PMCID: PMC5032984 DOI: 10.1111/dom.12481] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Revised: 04/14/2015] [Accepted: 04/28/2015] [Indexed: 11/27/2022]
Abstract
The aim of the present study was to determine the effects of luseogliflozin on 24-h glucose levels, assessed by continuous glucose monitoring, and on pharmacodynamic variables measured throughout the day. In this double-blind, placebo-controlled, crossover study, 37 patients with type 2 diabetes mellitus inadequately controlled with diet and exercise were randomized into two groups. Patients in each group first received luseogliflozin then placebo for 7 days each, or vice versa. After 7 days of treatment, the mean 24-h glucose level was significantly lower with luseogliflozin than with placebo [mean (95% confidence interval) 145.9 (134.4-157.5) mg/dl vs 168.5 (156.9-180.0) mg/dl; p < 0.001]. The proportion of time spent with glucose levels ≥70 to ≤180 mg/dl was significantly greater with luseogliflozin than with placebo [median (interquartile range) 83.2 (67.7-96.5)% vs 71.9 (46.9-83.3)%; p < 0.001] without inducing hypoglycaemia. The decrease in glucose levels was accompanied by reductions in serum insulin levels throughout the day.
Collapse
Affiliation(s)
- R Nishimura
- Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
| | - T Osonoi
- Naka Kinen Clinic, Ibaraki, Japan
| | | | | | - K Sugio
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| | - H Omiya
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Ubukata
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| | - S Sakai
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| | - Y Samukawa
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| |
Collapse
|
30
|
Saeki K, Watanabe M, Tsuboi M, Sugano S, Yoshitake R, Tanaka Y, Ong SM, Saito T, Matsumoto K, Fujita N, Nishimura R, Nakagawa T. Anti-tumour effect of metformin in canine mammary gland tumour cells. Vet J 2015; 205:297-304. [PMID: 25981932 DOI: 10.1016/j.tvjl.2015.04.026] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 04/07/2015] [Accepted: 04/19/2015] [Indexed: 01/06/2023]
Abstract
Metformin is an oral hypoglycaemic drug used in type 2 diabetes. Its pharmacological activity reportedly involves mitochondrial respiratory complex I, and mitochondrial respiratory complex inhibitors have a strong inhibitory effect on the growth of metastatic canine mammary gland tumour (CMGT) cell lines. It is hypothesised that metformin has selective anti-tumour effects on metastatic CMGT cells. The aim of this study was to investigate the in vitro effect of metformin on cell growth, production of ATP and reactive oxygen species (ROS), and the AMP-activated protein kinase (AMPK) mammalian target of rapamycin (mTOR) pathway in two CMGT clonal cell lines with different metastatic potential. In addition, transcriptome analysis was used to determine cellular processes disrupted by metformin and in vivo anti-tumour effects were examined in a mouse xenograft model. Metformin inhibited CMGT cell growth in vitro, with the metastatic clone (CHMp-5b) displaying greater sensitivity. ATP depletion and ROS elevation were observed to a similar extent in the metastatic and non-metastatic (CHMp-13a) cell lines after metformin exposure. However, subsequent AMPK activation and mTOR pathway inhibition were prominent only in metformin-insensitive non-metastatic cells. Microarray analysis revealed inhibition of cell cycle progression by metformin treatment in CHMp-5b cells, which was further confirmed by Western blotting and cell cycle analysis. Additionally, metformin significantly suppressed tumour growth in xenografted metastatic CMGT cells. In conclusion, metformin exhibited an anti-tumour effect in metastatic CMGT cells through AMPK-independent cell cycle arrest. Its mechanism of action differed in the non-metastatic clone, where AMPK activation and mTOR inhibition were observed.
Collapse
Affiliation(s)
- K Saeki
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - M Watanabe
- Department of Medical Genome Science, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa 277-8561, Japan
| | - M Tsuboi
- Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - S Sugano
- Department of Medical Genome Science, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa 277-8561, Japan
| | - R Yoshitake
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - Y Tanaka
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - S M Ong
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - T Saito
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - K Matsumoto
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - N Fujita
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - R Nishimura
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - T Nakagawa
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| |
Collapse
|
31
|
Maeda S, Saimura M, Minami S, Kurashita K, Nishimura R, Kai Y, Yano H, Tanaka T, Mitsuyama S, Tamura K. P171 Efficacy and safety of eribulin as first- to third-line treatment with HER2(–) MBC (KBC-SG 1105). Breast 2015. [DOI: 10.1016/s0960-9776(15)70212-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
32
|
Nakano M, Fujisue M, Tashima R, Okumura Y, Nishiyama Y, Ohsako T, Toyozumi Y, Arima N, Nishimura R. P244 Clinical and prognostic significance of menopausal status in triple negative breast cancer. Breast 2015. [DOI: 10.1016/s0960-9776(15)70276-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
33
|
Tashima R, Nishimura R, Arima N, Hujisue M, Nakano M, Okumura Y, Osako T, Toyozumi Y. P260 Evaluation of PgR expression as a prognostic factor in luminal HER2-negative breast cancer. Breast 2015. [DOI: 10.1016/s0960-9776(15)70292-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
34
|
Okumura Y, Nishimura R, Nakatsukasa K, Yoshida A, Masuda N, Tanabe M, Shien T, Tanaka S, Arima N, Komoike Y, Taguchi T, Iwase T, Inaji H, Ishitobi M. Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence. Eur J Surg Oncol 2015; 41:548-52. [PMID: 25682910 DOI: 10.1016/j.ejso.2015.01.030] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 01/07/2015] [Accepted: 01/19/2015] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Changes in the biological marker status between primary and recurrent tumors are observed in breast cancer. However, their clinical significance is still uncertain, especially for patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery. PATIENTS AND METHODS A total of 117 patients with IBTR without distant metastases were enrolled in this study. All patients were examined for estrogen receptor (ER), HER2, and Ki-67 in both the primary tumors and paired IBTR. We evaluated the impact of changes in these biomarkers between primary tumors and IBTR on the prognosis after IBTR. RESULTS There were no associations of changes in the ER, HER2 status with distant disease-free survival (DDFS) after surgical resection of IBTR, whereas the change in the Ki-67 status between the primary tumors and IBTR was significantly correlated with DDFS (unadjusted: p = 0.0094; adjusted: p = 0.013). Patients in the "increased or remained high" Ki-67 group had a significantly shorter DDFS than those in the "decreased or remained low" Ki-67 group (5-year DDFS: 55.5 vs. 79.3%, respectively, p = 0.0084 by log-rank test). CONCLUSION An increased or persistently high Ki-67 status in the IBTR was significantly correlated with a poorer prognosis after IBTR.
Collapse
Affiliation(s)
- Y Okumura
- Dept. of Breast & Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
| | - R Nishimura
- Dept. of Breast & Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan
| | - K Nakatsukasa
- Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - A Yoshida
- Dept. of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan
| | - N Masuda
- Dept. of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - M Tanabe
- Division of Breast Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Shien
- Dept. of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan
| | - S Tanaka
- Section of Breast and Endocrine Surgery, Department of General and Gastroenterological Surgery, Osaka Medical College, Osaka, Japan
| | - N Arima
- Dept. of Pathology, Kumamoto City Hospital, Kumamoto, Japan
| | - Y Komoike
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - T Taguchi
- Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - T Iwase
- Division of Breast Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - H Inaji
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - M Ishitobi
- Dept. of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
| | | |
Collapse
|
35
|
Funase Y, Fumisawa Y, Yamada M, Nishimura R, Oike Y, Toba K, Yazaki Y, Yokoyama T, Suzuki N, Seki K, Nishio SI, Hattori Y, Kamijo Y, Komatsu M, Yamauchi K, Aizawa T. V-shaped relationship between HbA1c and all-cause mortality in the elderly with type 2 diabetes. Eur Geriatr Med 2014. [DOI: 10.1016/j.eurger.2014.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Nishimura R, Goto M, Sekiguchi S, Fujimori K, Ushiyama A, Satomi S. Assessment for revascularization of transplanted pancreatic islets at subcutaneous site in mice with a highly sensitive imaging system. Transplant Proc 2014; 43:3239-40. [PMID: 22099766 DOI: 10.1016/j.transproceed.2011.09.095] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND The subcutaneous space is one of the ideal sites for pancreatic islet transplantation, owing to the minimal invasiveness and easy access. However, the results of pancreatic islet transplantation in subcutaneous sites remain unsatisfactory. One of the main obstacles to successful pancreatic islet transplantation in subcutaneous sites is poor revascularization. Therefore, the aim of this study was to evaluate the revascularization process at subcutaneous sites with a highly sensitive imaging system combining a dorsal skinfold chamber (DSC) technique and multiphoton laser scanning microscopy (MPLSM). METHODS A few pancreatic islets isolated from C57BL/6-Tg (CAG-EGFP) mice were syngeneically transplanted into nonmetallic DSCs mounted on the backs of C57BL/6J mice. Time-dependent changes in the newly formed vessels of pancreatic islets were imaged using MPLSM on days 1, 4, 7, 11, and 14 (n = 6). Texas Red was injected intravenously to visualize blood vessels. To evaluate islet graft revascularization, we measured vascular volume surrounding the islet using the Volocity system (Improvision). RESULTS The percentages of vascular volume at days 1 and 14 were assumed to be 0 and 100%, respectively. The vascular volume on each day was 9.4 ± 6.5% (day 4), 34.9 ± 11.2% (day 7), and 21.1 ± 4.6% (day 11). CONCLUSIONS The present study showed that a highly sensitive imaging system combining the DSC technique and MPLSM was a useful tool to analyze the revascularization process of pancreatic islets in a subcutaneous site.
Collapse
Affiliation(s)
- R Nishimura
- Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, Miyagi, Japan.
| | | | | | | | | | | |
Collapse
|
37
|
Tomita S, Terao Y, Hatano T, Nishimura R. Subtotal glossectomy preserving half the tongue base prevents taste disorder in patients with tongue cancer. Int J Oral Maxillofac Surg 2014; 43:1042-6. [DOI: 10.1016/j.ijom.2014.02.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 01/06/2014] [Accepted: 02/17/2014] [Indexed: 11/27/2022]
|
38
|
Toya R, Murakami R, Murakami D, Baba Y, Nishimura R, Matsuyama T, Saito T, Semba A, Yumoto E, Yamashita Y, Oya N. Radiation Therapy for Nasopharyngeal Carcinoma: Predictability of Treatment Outcomes at Interim Re-assessment. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
39
|
Ohno H, Nishimura N, Yamada K, Shimizu Y, Nishimura R, Iwase S, Sugenoya J, Sato M. Water nanodroplets make a greater contribution to facial skin moisture levels in air-conditioned rooms during winter than in summer. Skin Res Technol 2014; 21:207-13. [DOI: 10.1111/srt.12178] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/16/2014] [Indexed: 11/28/2022]
Affiliation(s)
- H. Ohno
- The Department of Physiology; School of Medicine; Aichi Medical University; Nagakute Japan
| | - N. Nishimura
- The Department of Physiology; School of Medicine; Aichi Medical University; Nagakute Japan
| | - K. Yamada
- Hitachi Appliances, Inc.; Tokyo Japan
| | - Y. Shimizu
- The Department of Physiology; School of Medicine; Aichi Medical University; Nagakute Japan
| | - R. Nishimura
- The Department of Physiology; School of Medicine; Aichi Medical University; Nagakute Japan
| | - S. Iwase
- The Department of Physiology; School of Medicine; Aichi Medical University; Nagakute Japan
| | - J. Sugenoya
- The Department of Physiology; School of Medicine; Aichi Medical University; Nagakute Japan
- Sugiyama Jogakuen University; Nagoya Japan
| | - M. Sato
- The Department of Physiology; School of Medicine; Aichi Medical University; Nagakute Japan
| |
Collapse
|
40
|
Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, Toyozumi Y, Arima N. Abstract P6-05-14: Prognostic significance of Ki-67 index value at primary breast tumor in recurrent breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-05-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The Ki-67 index value is a prognostic factor in primary breast cancer and is a proliferation marker that also distinguishes between luminal type A and type B breast cancer. Moreover, change in Ki-67 index value due to treatment and recurrence is considered to be important in treating breast cancer. The evaluative procedure in this study was on two levels; first, we examined whether the baseline Ki-67 value at the primary tumor is useful as a prognostic factor after recurrence, and second, we looked at the changes in the values after recurrence.
Patients and Methods: Immunohistochemical (IHC) analysis of the Ki-67 index was performed on 4701 patients with primary breast cancer from 1987 until March 2013 at Kumamoto City Hospital. Out of these patients, there were 666 consecutive cases with recurrence after primary surgery. The fraction of proliferating cells (positive for Ki-67) was based on a count of at least 500 tumor cells in the area including the hot spot, and the Ki-67 values were divided into 2 or 3 groups; <20% and ≥20% (and ≥50%). Items examined were ER, PgR, HER2, tumor size, nodal status at primary tumor, and recurrent site (soft tissue, bone and viscera) and disease-free interval (DFI). Cox's proportional hazard model was used to perform a univariate and multivariate analyses of the factors related to overall survival (OS) after recurrence. The median follow-up period was 65.9 months in the remaining survival group. In 101 recurrent cases from whom the recurrent lesion was resected, the change in biological markers (Ki-67, ER and PgR) were evaluated.
Results: The median Ki-67 value at baseline was 20% in all the cases and 27% in the recurrent cases. In terms of recurrent site, the values were low (23%) in patients with bone metastasis, whereas patients with liver or brain metastasis showed higher values (38% and 53%, respectively). Moreover, DFI was inversely correlated with Ki-67 values. Univariate and multivariate analyses were performed to identify the prognostic factors for OS after recurrence. The significant factors included tumor size, lymph node status, ER, PgR, DFI, recurrent site, and the Ki-67 index value. Among these factors, a multivariate analysis revealed that the Ki-67 index value at primary tumor was an independent significant factor. The hormone receptor positive rate from the primary tumor to recurrence decreased from 67.3% to 63.4% and 64.4% to 50% for ER and PgR, respectively. The Ki-67 index value increased significantly from a mean of 28.9% at primary tumor to 35.7% at relapse. Furthermore, the Ki-67 index value at primary tumor was a significant prognostic factor for OS after recurrence in this cohort.
Conclusion: The Ki-67 value at primary tumor was a significant prognostic factor for OS after recurrence. The Ki-67 index value increased significantly after recurrence. It is therefore important to take the Ki-67 index into consideration in the treatment and follow-up of breast cancer patients.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-05-14.
Collapse
Affiliation(s)
- R Nishimura
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - T Osako
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - Y Nishiyama
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - R Tashima
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - M Nakano
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - M Fujisue
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - Y Toyozumi
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - N Arima
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| |
Collapse
|
41
|
Fujisue M, Nishimura R, Nakano M, Tashima R, Nishiyama Y, Osako T, Toyozumi Y, Arima N. Abstract P5-05-06: Menopausal status: An important consideration in determining the biology and prognosis of estrogen receptor-positive and progesterone receptor-negative breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-05-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Transcription of the progesterone receptor (PgR) gene is regulated by estrogen in the breast tissue. PgR loss is considered to be a result in the reduction of estrogen receptor (ER) activity, due to either low circulating estrogen in some older women or a high growth factor signaling. Among the ER-positive breast cancer patients, PR-negative cases frequently have a higher resistance to endocrine therapy, and have a poorer prognosis. Therefore, we examined the clinical significance of ER+/PgR- tumors in luminal/HER2 negative breast cancer and its relationship to menopausal status.
Methods: The sample for this study came from 1791 consecutive patients with HER2 negative primary breast cancer from January 2002 to March 2013. The ER and PgR expressions were evaluated using immunohistochemistry (IHC). 1586cases had ER+/PgR+ tumor, 205cases had ER+/PgR- tumor. The items examined were nuclear grade, Ki-67 index value, TP53, tumor size and number of lymph node involvement. The Ki-67 index value and TP53 were evaluated using IHC and the cut-off values were 20% and 50%, respectively. Recurrence free survival (RFS) and breast cancer-specific survival (BCSS) was calculated using the Kaplan-Meier method and evaluated by the log-rank test or generalized Wicoxon test in stage 1 and 2 breast cancer.
Results: In terms of the distribution of ER and PgR status, ER+/PgR- were frequently seen in postmenopausal patients (13.7% vs 6.8%, respectively). Patients with ER+/PgR-and HER2 negative tumors had significantly smaller tumors, lower Ki-67 values, and a lower nuclear grade in the postmenopausal group compared with those in the premenopausal group. Moreover, RFS trended to be better in the postmenopausal group (p = 0.06), but there was no significant difference. BCSS was significantly higher in the postmenopausal cases (p = 0.001). On the other hand, in patients with ER+/PgR+ tumors, there was no significant difference in RFS and BCSS between the post- and pre-menopausal groups.
Conclusion: The ER+/PgR- tumors were more commonly seen in postmenopausal patients. The biological characteristics of ER+/PgR- tumors were significantly different in terms of the Ki-67 index value, nuclear grade, and the prognosis (BCSS and RFS) between pre- and postmenopausal status. Moreover, the postmenopausal group had a more favorable biology and prognosis than the premenopausal group. Therefore, the findings in this study indicate that menopausal status is related to the biology and prognosis in patients with ER+/PgR- tumors.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-05-06.
Collapse
Affiliation(s)
- M Fujisue
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - R Nishimura
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - M Nakano
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - R Tashima
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - Y Nishiyama
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - T Osako
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - Y Toyozumi
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| | - N Arima
- Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan
| |
Collapse
|
42
|
Arima N, Toyozumi Y, Nishimura R, Osako T, Nishiyama Y, Nakano M, Fujisue M, Tashima R, Moriya T. Abstract P1-02-01: Pre-analytical setting is critical for an assessment of the Ki-67 labeling index for breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-02-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The Ki-67 labeling index (LI) is useful in determining the efficacy of chemotherapy for patients with ER-positive and HER2-negative breast cancer. However, standardization of Ki-67 assessment has not yet been established. In terms of the factors that may affect Ki-67 LI, recent studies have focused on inter-observer variability in the interpretation of these values and insufficient attention has been given to the importance of handling the tissue. Therefore, this study focused on the effect of tissue fixation on Ki-67 LI.
Methods:
The effects of several pre-analytical conditions on the Ki-67 LI were studied as follows;
(1) Type of fixation: Each 173 surgically excised tumors were fixed with either 10% neutral buffered formalin or 15% formalin on the same condition, followed by assessment of Ki-67 LI.
(2) Time of fixation: Each study was repeated more than three times to confirm the result.
A: Time to fixation: A part of tumor, sliced from the surgically excised tumor, was kept in 4° for several hours to overnight before formalin fixation. Ki-67 LI was compared between the tumor with immediate and delayed fixation.
B: Time of fixation:
Insufficient fixation: A part of tumor, sliced from the surgically excised tumor, was fixed with formalin for 3 hours, followed by preparation of a paraffin-embedded block. Ki-67 LI was compared between the tumor with proper and shorter fixation.
Prolonged fixation: Some pieces of slice were prepared from the surgically excised tumor, followed by each preparation of a paraffin-embedded block at a designated fixation period. Ki-67 LI was compared among each sample fixed in a different period of time.
(3) Surgically excised tumors on Ki-67 LI:
A: Effect of cutting onto the tumor before fixation: Ki-67 LI in each 595 surgically excised tumor with or without cutting onto the tumor before fixation, was analyzed.
B: Comparison between core needle biopsy and surgically excised tissue: Ki-67 LI in each 136 pairs of core needle biopsy and surgically excised tissue originated from the same tumor was compared.
Results:
(1) Ki-67 LI was significantly higher when 10% neutral buffered formalin was used as a fixative compared to 15% formalin (p = 0.018).
(2) Ki-67 LI was reduced in some degree when time to fixation was delayed, while insufficient fixation caused dramatic reduction of Ki-67 LI compared to that seen in an either ER or HER2. A prolonged period of fixation caused gradual reduction of Ki-67 LI associated with diminished nuclear labeling.
(3) Ki-67 LI was significantly higher in the tumor cut onto before fixation (p = 0.018). There was no significant difference in Ki-67 LI between core needle and surgically excised specimens (p = 0.107), when the tumor was properly fixed.
Conclusion: Our results suggest that pre-analytical setting critically influences the Ki-67 labeling. In order to standardize Ki-67 LI assessment in breast cancer, the care in handling of the pre-analytical tissue is crucial in determining accurate Ki-67 values.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-02-01.
Collapse
Affiliation(s)
- N Arima
- Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan
| | - Y Toyozumi
- Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan
| | - R Nishimura
- Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan
| | - T Osako
- Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan
| | - Y Nishiyama
- Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan
| | - M Nakano
- Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan
| | - M Fujisue
- Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan
| | - R Tashima
- Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan
| | - T Moriya
- Kumamoto City Hospital, Kumamoto, Japan; Kawasaki Medical University, Kurashiki, Okayama, Japan
| |
Collapse
|
43
|
Ohtani S, Masuda N, Im YH, Im SA, Park BW, Kim SB, Yanagita Y, Takao S, Ohno S, Aogi K, Iwata H, Yoshidome K, Nishimura R, Ohashi Y, Lee SJ, Toi M. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: First safety analysis of CREATE-X (JBCRG-04). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Patients (pts) without pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) have a poor prognosis compared with pts achieving a pCR with NAC. It is not clear whether further systemic chemotherapy is beneficial for pts with no pCR. CREATE-X (UMIN000000843) is an ongoing collaborative Korean (KRN)/Japanese (JPN) prospective multicenter open-label randomized phase III trial evaluating this clinical question using capecitabine (X) in pts with no pCR after NAC. We report first safety results, focusing on hand-foot syndrome (HFS), the timing of radiotherapy (RT) and hormone therapy (HT), and differences between KRN and JPN pts.
Methods
Pts with residual invasive cancer after anthracycline- and/or taxane-containing NAC were randomized to standard post-surgical treatment (RT, HT as appropriate) with or without 8 cycles of X (1250 mg/m2 bid, days 1–14 q3w). RT was given before or after X. Pts with hormone receptor (HR)-positive disease received HT either with or after X, according to each center's prespecified standard practice. After evaluation of the tolerability of 6 cycles of X in the first 50 pts, the independent data monitoring committee recommended extending X to 8 cycles.
Results
Between Feb 2007 and Jul 2012, 910 pts were enrolled (304 in Korea, 606 in Japan). At the time of data cut-off (May 20, 2013), data were available from 866 pts. Median age was 48 years in both arms. In the investigational arm, RT was given before X in 260 pts and after X in 33 pts; 73 pts received prophylactic vitamin B6 (VB6). In HR-positive pts HT was given with X in 200 pts and after X in 24 pts. The relative dose intensity of X was 85.7% in JPN pts and 95.2% in KRN pts. Grade (G) 3/4 neutropenia, HFS (G3 only), fatigue, and diarrhea were significantly (p<0.05) more common with X than no X. G3 HFS occurred in 11.1% of pts receiving X, and was significantly more common in JPN vs KRN pts (p = 0.016). No significant difference in HFS was observed between pts who received vs did not receive VB6 (p = 0.392). G3/4 alanine aminotransferase (ALT) abnormalities were significantly more common in pts receiving RT after vs before X (p<0.001) and in pts receiving HT after vs concurrently with X (p<0.001).
n/N(%) Investigational armControl arm (n = 430)(n = 436)HR status Positive275/430(64)275/436(63)Negative141/430(33)143/436(33)Unknown14/430(3)18/436(4)G 3/4 toxicity Neutropenia36/385(9)5/326(2)Fatigue6/426(1)0/417(0)Diarrhea12/426(3)1/417(<1)HFS(G3)47/424(11)0 JPN40/296(14)0 KRN7/128(5)0 VB66/73(8)- No VB641/351(12)-ALT abnormality10/409(2)3/391(<1) with RT8/285(3)1/280(<1) X → RT8/31(26)- RT → X0/254(0)- without RT2/124(2)2/111(2) with HT2/214(1)1/267(<1) X + HT0/190(0)- X → HT2/24(8)- wothout HT8/195(4)2/124(2)
Conclusions
Addition of 8 cycles of X to standard adjuvant therapy is feasible and tolerable, resulting in a modest yet acceptable increase in toxicities. The timing of RT and HT administration relative to X influenced the incidence of adverse events. HFS was more common in JPN than KRN pts, although further investigation of the potential cause of this difference is required. These findings should be interpreted in light of efficacy data, expected in 2015.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-12-03.
Collapse
Affiliation(s)
- S Ohtani
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - N Masuda
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - Y-H Im
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - S-A Im
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - B-W Park
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - S-B Kim
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - Y Yanagita
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - S Takao
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - S Ohno
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - K Aogi
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - H Iwata
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - K Yoshidome
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - R Nishimura
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - Y Ohashi
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - S-J Lee
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| | - M Toi
- Hiroshima City Hospital, Hiroshima, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Yonsei University Severance Hospital, Seoul, Korea; Asan Medical Center, Seoul, Korea; Gunma Prefectural Cancer Center, Gunma, Japan; Hyogo Cancer Center, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; National Hospital Organizaton Shikoku Cancer Center, Ehime, Japan; Aichi Cancer Center, Aichi, Japan; Osaka Police Hospital, Osaka, Japan; Kumamoto Municipal Hospital, Kumamoto, Japan; Tokyo University, Tokyo, Japan; Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|
44
|
Fukushima K, Kanemoto H, Ohno K, Takahashi M, Fujiwara R, Nishimura R, Tsujimoto H. Computed tomographic morphology and clinical features of extrahepatic portosystemic shunts in 172 dogs in Japan. Vet J 2013; 199:376-81. [PMID: 24512983 DOI: 10.1016/j.tvjl.2013.11.013] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 09/26/2013] [Accepted: 11/17/2013] [Indexed: 11/18/2022]
Abstract
Canine extrahepatic congenital portosystemic shunts (EH-cPSS) are classified into several anatomical types, depending on the origin and termination of the shunt vessel. The aim of this retrospective study was to determine the proportion and clinical features of each anatomical shunt type in a population of dogs presented to a veterinary teaching hospital in Japan. Dogs diagnosed with EH-cPSS using computed tomographic (CT) portography were included (n=172) and shunts were classified based on previous reports. Clinical data were collected from case records and analysed statistically. The most common anatomical type was the spleno-phrenic shunt (n=64), followed by the spleno-azygos (n=38), right gastric-caval (n=29), spleno-caval (n=21), right gastric-caval with caudal loop (n=9), right gastric-phrenic (n=6), colono-caval (n=3), spleno-phrenic and azygos (n=1), and porto-caval (n=1) shunts. Spleno-phrenic and spleno-azygos shunts were diagnosed more frequently in older dogs than right gastric-caval and spleno-caval shunts (P<0.05). The portal vein/aortic (PV/Ao) ratio was significantly larger in dogs with spleno-phrenic shunts than in dogs with spleno-azygos, right gastric-caval or spleno-caval shunts (P<0.05). The PV/Ao ratio was significantly larger in dogs with spleno-azygos shunts than in dogs with right gastric-caval shunts. Dogs with spleno-phrenic shunts had significantly lower serum alkaline phosphatase activities than those with right gastric-caval or spleno-caval shunts. Dogs with spleno-phrenic shunts had significantly lower fasting ammonia concentrations than those with spleno-caval shunts.
Collapse
Affiliation(s)
- K Fukushima
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - H Kanemoto
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - K Ohno
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
| | - M Takahashi
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - R Fujiwara
- Department of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - R Nishimura
- Department of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| | - H Tsujimoto
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
| |
Collapse
|
45
|
Yamamoto S, Kozuki T, Harada D, Ohashi K, Kitajima H, Nogami N, Nishimura R, Teramoto N, Takigawa N, Shinkai T. A Case of Extra-Skeletal Ewing Sarcoma Elevated with Plasma Pro-GRP and Serum CA125. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Yanagawa M, Fukatsu K, Mitsui T, Amenomori S, Murakoshi S, Yasuhara H, Nishimura R. PP210-SUN EFFECTS OF A NEW IMMUNE-MODULATING DIET ENRICHED WITH WHEY-HYDROLYZED PEPTIDE, FERMENTED MILK, AND ISOMALTULOSE ON PLASMA AND INTESTINAL CYTOKINE LEVELS IN MICE. Clin Nutr 2013. [DOI: 10.1016/s0261-5614(13)60255-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
47
|
Choisunirachon N, Jaroensong T, Yoshida K, Saeki K, Mochizuki M, Nishimura R, Sasaki N, Nakagawa T. Effects of low-dose cyclophosphamide with piroxicam on tumour neovascularization in a canine oral malignant melanoma-xenografted mouse model. Vet Comp Oncol 2013; 13:424-32. [DOI: 10.1111/vco.12059] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- N. Choisunirachon
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences; The University of Tokyo; Tokyo Japan
- Department of Veterinary Surgery; Faculty of Veterinary Science, Chulalongkorn University; Bangkok Thailand
| | - T. Jaroensong
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences; The University of Tokyo; Tokyo Japan
- Department of Companion Animal Clinical Sciences; Faculty of Veterinary Medicine, Kasetsart University; Bangkok Thailand
| | - K. Yoshida
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences; The University of Tokyo; Tokyo Japan
| | - K. Saeki
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences; The University of Tokyo; Tokyo Japan
| | - M. Mochizuki
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences; The University of Tokyo; Tokyo Japan
| | - R. Nishimura
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences; The University of Tokyo; Tokyo Japan
| | - N. Sasaki
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences; The University of Tokyo; Tokyo Japan
| | - T. Nakagawa
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences; The University of Tokyo; Tokyo Japan
| |
Collapse
|
48
|
Shimada M, Nishimura R, Hatae M, Hiura M, Takehara K, Tase T, Yamada H, Kurachis H, Sugiyama T, Kigawa J. Comparison of adjuvant chemotherapy and radiotherapy in patients with cervical adenocarcinoma of the uterus after radical hysterectomy: SGSG/TGCU Intergroup surveillance. EUR J GYNAECOL ONCOL 2013; 34:425-428. [PMID: 24475576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
PURPOSE The authors conducted this retrospective study to evaluate the efficacy of radiotherapy (RT) for high-risk patients with adenocarcinoma (AC) compared with chemotherapy (CT) after radical hysterectomy. MATERIALS AND METHODS There were 263 patients with AC and 58 with adenosquamous cell carcinoma (ASCC). Of these 321 patients, 151 received adjuvant treatment. Of these 151 patients, 69 received radiotherapy (RT) alone, including concurrent chemoradiotherapy (CCRT) with weekly cisdiamminedichloroplatinum (CDDP), 64 patients received CT alone, and 18 patients received concomitant RT and CT (RT + CT). RESULTS The five-year overall survival (OS) was 70.9% for patients receiving RT, 79.2% for CT, and 66.2% for RT + CT. Adjuvant treatment did not affect the incidence or the pattern of recurrence. The incidence of lymph node involvement was 9.0% in Stage Ib1, 23.9% in Stage Ib2, 30.8% in Stage IIa, and 41.2% in Stage IIb. CONCLUSIONS Adjuvant CT may be effective for high-risk patients with cervical adenocarcinoma.
Collapse
Affiliation(s)
- M Shimada
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
| | - R Nishimura
- Department of Gynecology, Hyogo Cancer Center, Akashi, Japan
| | - M Hatae
- Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima, Japan
| | - M Hiura
- Department of Gynecology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - K Takehara
- Department of Obstetrics and Gynecology, National Hospital Organization Kure Medical Center, Kure, Japan
| | - T Tase
- Department of Gynecology, Miyagi Cancer Center, Natori, Japan
| | - H Yamada
- Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan
| | - H Kurachis
- Department of Obstetrics and Gynecology, Yamagata University, Yamagata, Japan
| | - T Sugiyama
- Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan
| | - J Kigawa
- Department of Cancer Center, Tottori University Hospital, Yonago, Japan
| |
Collapse
|
49
|
Nishimura R, Yamaguchi M, Watanabe R, Toh U, Koga K, Shirahane K, Yoshinaga Y, Sasaki H, Tamura K, Mitsuyama S. 370 Lifestyle and Change in Bone Mineral Density in Japanese Postmenopausal Women with Hormone Receptor-positive Breast Cancer Before and After 1 Year of Aromatase Inhibitor Treatment. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70436-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
50
|
Okubo J, Takita J, Chen Y, Oki K, Nishimura R, Kato M, Sanada M, Hiwatari M, Hayashi Y, Igarashi T, Ogawa S. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. Oncogene 2012; 31:4667-76. [PMID: 22249260 DOI: 10.1038/onc.2011.616] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Anaplastic lymphoma kinase (ALK) was originally identified from a rare subtype of non-Hodgkin's lymphomas carrying t(2;5)(p23;q35) translocation, where ALK was constitutively activated as a result of a fusion with nucleophosmin (NPM). Aberrant ALK fusion proteins were also generated in inflammatory fibrosarcoma and a subset of non-small-cell lung cancers, and these proteins are implicated in their pathogenesis. Recently, ALK has been demonstrated to be constitutively activated by gene mutations and/or amplifications in sporadic as well as familial cases of neuroblastoma. Here we describe another mechanism of aberrant ALK activation observed in a neuroblastoma-derived cell line (NB-1), in which a short-form ALK protein (ALK(del2-3)) having a truncated extracellular domain is overexpressed because of amplification of an abnormal ALK gene that lacks exons 2 and 3. ALK(del2-3) was autophosphorylated in NB-1 cells as well as in ALK(del2-3)-transduced cells and exhibited enhanced in vitro kinase activity compared with the wild-type kinase. ALK(del2-3)-transduced NIH3T3 cells exhibited increased colony-forming capacity in soft agar and tumorigenicity in nude mice. RNAi-mediated ALK knockdown resulted in the growth suppression of ALK(del2-3)-expressing cells, arguing for the oncogenic role of this mutant. Our findings provide a novel insight into the mechanism of deregulation of the ALK kinase and its roles in neuroblastoma pathogenesis.
Collapse
Affiliation(s)
- J Okubo
- Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|